Chondroitin Sulfate

Nutritional Support for Structure and Function of Connective Tissue

DESCRIPTION

Chondroitin Sulfate capsules, provided by Douglas Laboratories®, contain 300 mg of chondroitin sulfate which may support the structure and function of joint cartilage as well as other connective tissue.

FUNCTIONS

Chondroitin sulfate is a glycosaminoglycan formed naturally by the body for the synthesis and maintenance of connective tissue. Glycosaminoglycans, formerly termed mucopolysaccharides, are an integral component of all connective tissues. Connective tissues have various functions in the body. They support internal organs and connect bones to each other (ligaments), form bone, cartilage, and the walls of blood vessels, attach muscles to bones (tendons), and replace tissues that have been damaged.

The two primary components of connective tissue are collagen and proteoglycans. Collagen is the strong, fibrous protein that physically connects our tissues. Proteoglycans are large carbohydrate-rich structures, resembling a bottle-brush in three-dimensional structure, i.e. a central protein rod with many strings of glucosamine-containing glycosaminoglycans extending outwards. Proteoglycans hold large amounts of water forming a stiff gel by virtue of their dense negative charges from sulfates. Proteoglycans link to collagen fibers to help form connective tissues. They provide resiliency, load distribution, shock-absorbing, compressive, and lubricating properties to connective tissues and joints.

Chondroitin sulfate is supportive and protective of connective tissues in numerous ways. It is an excellent source of n-acetylgalactoaminoglycan for the synthesis and protection of proteoglycans associated with cartilage tissues. Chondroitin sulfate also protects existing cartilage by reducing water loss from the proteoglycan-formed gel and by inhibiting enzymatic breakdown of cartilage.

It is not yet clear to what degree chondroitin sulfate is absorbed. Of concern is the size of the chondroitin sulfate molecule — in particular if it is too large to cross the intestinal lining. However, studies finding elevated plasma values of chondroitin sulfate following oral administration, in addition to studies demonstrating the benefits of orally administered chondroitin sulfate, support the bioavailability of this supplement.

INDICATIONS

Chondroitin sulfate may be a useful nutritional adjunct for individuals who wish to support the structure and function of the body's connective tissues, such as skin, tendons, ligaments, bone, and cartilage.

FORMULA (#7065)

SUGGESTED USE

Adults take 1 capsule daily or as directed by physician.

SIDE EFFECTS

No adverse side effects have been reported.

STORAGE

Store in a cool, dry place, away from direct light. Keep out of reach of children.

Chondroitin Sulfate

Nutritional Support for Structure and Function of Connective Tissue

REFERENCES

Alekseeva LI, Benevolenskaia LI, Nasonov EL, Chichasova NV, Kariakin AN. [Structum (chondroitin sulfate)--a new agent for the treatment of osteoarthrosis]. Ter Arkh 1999;71:51-3.

Bourgeois P, Chales G, Dehais J, Delcambre B, Kuntz JL, Rozenberg S. Efficacy and tolerability of chondroitin sulfate 1200 mg/day vs chondroitin sulfate 3 x 400 mg/day vs placebo. Osteoarthritis Cartilage 1998;6 Suppl A:25-30.

Bucsi L, Poor G. Efficacy and tolerability of oral chondroitin sulfate as a symptomatic slow-acting drug for osteoarthritis (SYSADOA) in the treatment of knee osteoarthritis. Osteoarthritis Cartilage 1998;6 Suppl A:31-6. Conte A, Volpi N, Palmieri L, Bahous I, Ronca G. Biochemical and pharmacokinetic aspects of oral treatment with chondroitin sulfate. Arzneimittelforschung 1995;45:918-25.

Deal CL, Moskowitz RW. Nutraceuticals as therapeutic agents in osteoarthritis. The role of glucosamine, chondroitin sulfate, and collagen hydrolysate. Rheum Dis Clin North Am 1999;25:379-95.

Fillmore CM, Bartoli L, Bach R, Park Y. Nutrition and dietary supplements [In Process Citation]. Phys Med Rehabil Clin N Am 1999;10:673-703.

Hardingham T. Chondroitin sulfate and joint disease. Osteoarthritis Cartilage 1998;6 Suppl A:3-5. Kelly GS. The role of glucosamine sulfate and chondroitin sulfates in the treatment of degenerative joint disease. Altern Med Rev 1998;3:27-39.

Leeb BF, Petera P, Neumann K. [Results of a multicenter study of chondroitin sulfate (Condrosulf) use in arthroses of the finger, knee and hip joints]. Wien Med Wochenschr 1996;146:609-14.

Leffler CT, Philippi AF, Leffler SG, Mosure JC, Kim PD. Glucosamine, chondroitin, and manganese ascorbate for degenerative joint disease of the knee or low back: a randomized, double-blind, placebo-controlled pilot study. Mil Med 1999;164:85-91.

Mazieres B, Loyau G, Menkes CJ, Valat JP, Dreiser RL, Charlot J, Masounabe-Puyanne A. [Chondroitin sulfate in the treatment of gonarthrosis and coxarthrosis. 5-months result of a multicenter double-blind controlled prospective study using placebo]. Rev Rhum Mal Osteoartic 1992;59:466-72.

Morreale P, Manopulo R, Galati M, Boccanera L, Saponati G, Bocchi L. Comparison of the antiinflammatory efficacy of chondroitin sulfate and diclofenac sodium in patients with knee osteoarthritis. J Rheumatol 1996;23:1385-91.

Pipitone VR. Chondroprotection with chondroitin sulfate. Drugs Exp Clin Res 1991;17:3-7.

Ronca F, Palmieri L, Panicucci P, Ronca G. Anti-inflammatory activity of chondroitin sulfate. Osteoarthritis Cartilage 1998;6 Suppl A:14-21.

Shankland WE, 2nd. The effects of glucosamine and chondroitin sulfate on osteoarthritis of the TMJ: a preliminary report of 50 patients. Cranio 1998;16:230-5.

Uebelhart D, Thonar EJ, Delmas PD, Chantraine A, Vignon E. Effects of oral chondroitin sulfate on the progression of knee osteoarthritis: a pilot study. Osteoarthritis Cartilage 1998;6 Suppl A:39-46.

Verbruggen G, Cornelissen M, Elewaut D, Broddelez C, De Ridder L, Veys EM. Influence of polysulfated polysaccharides on aggrecans synthesized by differentiated human articular chondrocytes. J Rheumatol 1999;26:1663-71.

Verbruggen G, Goemaere S, Veys EM. Chondroitin sulfate: S/DMOAD (structure/disease modifying antiosteoarthritis drug) in the treatment of finger joint OA. Osteoarthritis Cartilage 1998;6 Suppl A:37-8.

For more information on **PRODUCT NAME HERE (change to Grey font)** visit douglaslabs.com

† These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Manufactured by Douglas Laboratories 600 Boyce Road Pittsburgh, PA 15205 800-245-4440 douglaslabs.com



You trust Douglas Laboratories. Your patients trust you.